肺表面活性物质
片状颗粒
肺
糖蛋白
肾
免疫系统
细胞生物学
生物标志物
生物
化学
免疫学
病理
医学
生物化学
内科学
内分泌学
作者
Skylar D. King,Shi‐You Chen
出处
期刊:American Journal of Physiology-cell Physiology
[American Physiological Society]
日期:2020-07-08
卷期号:319 (2): C316-C320
被引量:26
标识
DOI:10.1152/ajpcell.00195.2020
摘要
Pulmonary surfactant is a heterogeneous active surface complex made up of lipids and proteins. The major glycoprotein in surfactant is surfactant protein A (SP-A), which is released into the alveolar lumen from cytoplasmic lamellar bodies in type II alveolar epithelial cells. SP-A is involved in phospholipid absorption. SP-A together with other surfactant proteins and phospholipids prevent alveolar collapse during respiration by decreasing the surface tension of the air-liquid interface. Additionally, SP-A interacts with pathogens to prevent their propagation and regulate host immune responses. Studies in human and animal models have shown that deficiencies or mutations in surfactant components result in various lung or kidney pathologies, suggesting a role for SP-A in the development of lung and kidney diseases. In this mini-review, we discuss the current understanding of SP-A functions, recent findings of its dysfunction in specific lung and kidney pathologies, and how SP-A has been used as a biomarker to detect the outcome of lung diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI